Home World News FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory... World News FDA Approves Brentuximab Vedotin with Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma By Ogkologos - March 27, 2025 741 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHELON-3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Data from a Large Cohort of Patients with mRCC Demonstrate the... September 21, 2020 Opportunity and mentorship: Our new PhD programme aiming to open-up academia... July 22, 2022 Shortening Duration of Adjuvant Treatment from 6 to 3 Months Did... May 10, 2022 FDA Approves Amivantamab and Hyaluronidase-lpuj for Subcutaneous Injection January 14, 2026 Load more HOT NEWS A Positive Trend in OS Improvement Favours Atezolizumab Compared to Best... 2022 ASCO Annual Meeting Research Round Up: Advances in Treating Genitourinary... Talking About Your Sexual Orientation and Gender Identity With Your Cancer... New Super-Microsurgical Procedure May Prevent Lymphedema in Breast Cancer Patients